Information and actions for the relief and cure of Parkinson 's disease  |  contact/imprint  |  data privacy

  • Home
  • Blog
  • New Active Ingredient against Alpha Synuclein in Clinical Study with Promising Results

Alpha-Synuclein is one of the body’s own proteins which occurs in higher concentrations in Parkinson’s sufferers, and so probably damages neurons in the brain.
The Irish company Prothena Corporation plc has developed an active ingredient that reduces alpha synucleins in the blood by 96% after a single dose. The active ingredient is called PRX002 and is currently being tested in phase 1 of a clinical study (see press release). This is showing that PRX002 in different doses is being tolerated well by the study participants and is bringing about the desired reduction in the alpha synuclein levels.